Stay updated on Pembrolizumab Plus Epacadostat vs Standard of Care Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus Epacadostat vs Standard of Care Clinical Trial page.

Latest updates to the Pembrolizumab Plus Epacadostat vs Standard of Care Clinical Trial page
- CheckyesterdayChange DetectedThe site footer revision changed from v3.8.0 to v3.8.1. The study details remain unchanged.SummaryDifference0.0%

- Check8 days agoChange DetectedThe clinical trial record for pembrolizumab plus epacadostat versus standard-of-care treatment in metastatic renal cell carcinoma is displayed, with study design, eligibility, outcomes, participating locations, and record documents. It indicates that the study is completed and no longer recruiting.SummaryDifference100%

- Check15 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide notice about NIH terminology updates was added, and the site revision label changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check43 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier advances from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check57 days agoChange DetectedAccess to the study record is blocked by a 403 Forbidden page, replacing the previous full content and navigation with a minimal header. Users can no longer view the study details and related links on this page.SummaryDifference17%

Stay in the know with updates to Pembrolizumab Plus Epacadostat vs Standard of Care Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Epacadostat vs Standard of Care Clinical Trial page.